Minerva Neurosciences: Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback

(marketscreener.com) By Colin Kellaher Minerva Neurosciences shares lost more than half of their value in early trading Tuesday after the U.S. Food and Drug Administration once again turned away the company's application seeking approval of its lead drug candidate. Shares of the Burlington, Mass., clinical-stage biopharmaceutical company were recently...https://www.marketscreener.com/quote/stock/MINERVA-GROUP-HOLDING-LIM-27114542/news/Minerva-Neurosciences-Shares-Slide-on-Latest-FDA-Roluperidone-Setback-46040170/?utm_medium=RSS&utm_content=20240227